Previous 10 | Next 10 |
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations – – Newly identified cell surface proteins play a role in SARS-CoV-2 infectio...
Investing in the biotech industry can be a long road to gains given the sector’s volatility. Even with a good understanding of the system, no one can predict which biotechnology treatment, device or therapy will give the biggest return, which makes biotechnology exchange-tr...
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on Tuesday, April 13 th ...
Vir Biotechnology (VIR) announces new preclinical research demonstrating the ability of VIR-7831, the company’s investigational SARS-CoV-2 monoclonal antibody (mAb), to maintain its neutralizing activity against a mutation in the receptor binding domain ((RBD)) of SARS-CoV-2.Study resu...
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern – – Plasma from vaccinated individuals and several therapeutic monoclonal antibodies showed a reduction in neutraliza...
Eli Lilly (LLY), Vir Biotechnology (VIR) and GlaxoSmithKline (GSK) announce topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19.Results showed that bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK...
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 - In combination, the two monoclonal antibodies demonstrated a 70% relative reduction in persistently high viral ...
The rise in thematic ETFs in 2020 was remarkable, with assets increasing by 78% in Q4 alone, to $104B in AUM. This meteoric growth has been powered by firms like Defiance, a relative newcomer to the ETF space that has already produced a $1B fund in FIVG. Founded in 2018 by a group...
GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announced the submission of an application to the FDA requesting the Emergency Use Authorization (“EUA”) for VIR-7831, a SARS-CoV-2 monoclonal antibody.The companies have applied the EUA for VIR-7831 to treat those abov...
LONDON and SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for VIR-783...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...